31.05.2014 22:29:57
|
Nektar Therapeutics: NKTR-102 Exceeds Primary Endpoint In Phase 2 Study
(RTTNews) - Nektar Therapeutics (NKTR) announced new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma.
The trial enrolled 20 patients with high-grade glioma from August 2012 to May 2013. The primary endpoint was met and exceeded with fifty-five percent of patients in the study achieving six-week progression-free survival, the company said.
NKTR-102 monotherapy was well-tolerated in patients with Avastin-refractory high-grade glioma with low toxicity in spite of being heavily pre-treated and neurologically symptomatic, Nektar said. Hematologic toxicity was mild.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nektar Therapeuticsmehr Nachrichten
Analysen zu Nektar Therapeuticsmehr Analysen
Aktien in diesem Artikel
Nektar Therapeutics | 0,66 | -3,17% |
|